Cellectis

Cellectis Operating Expenses

The Total Operating Expenses of Cellectis (CLLS) as of Nov 20, 2026 is 102.11 M USD. In the previous year, Total Operating Expenses was 98.96 M USD — a change of 3.19% (higher).

Operating Expenses

102.11 MUSD

YoY

3.19%

Last updated:

Total Operating Expenses of Cellectis is 2025 102.11 M USD. Total Operating Expenses of Cellectis was 2024 98.96 M USD. It decreases by 3.19% higher compared to the previous year.

The Cellectis Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2018
123.81 M USD
Jan 1, 2019
135.06 M USD
Jan 1, 2020
131.15 M USD
Jan 1, 2021
124.82 M USD
Jan 1, 2022
115.00 M USD
Jan 1, 2023
95.77 M USD
Jan 1, 2024
98.96 M USD
Jan 1, 2025
102.11 M USD
The Cellectis Operating Expenses history
YEAROperating ExpensesYoY
102.11 MUSD+3.19%
98.96 MUSD+3.33%
95.77 MUSD-16.72%
115.00 MUSD-7.87%
124.82 MUSD-4.83%
131.15 MUSD-2.89%
135.06 MUSD+9.08%
123.81 MUSD-0.13%
123.98 MUSD+7.04%
115.82 MUSD+33.01%
87.08 MUSD+160.21%
33.46 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cellectis Stock analysis

What does Cellectis do? Cellectis SA develops gene-editing based products for immuno-oncology and gene therapy, targeting specific cancer indications. The company's product portfolio includes BALLI-01 for relapsed or refractory acute lymphoblastic leukemia (r/r ALL), NatHaLi-01 for relapsed or refractory B-cell Non-Hodgkin's Lymphoma (B-NHL), ALPHA3 for Large B-Cell Lymphoma (LBCL), TRAVERSE for advanced or metastatic clear cell renal cell carcinoma (RCC), and Melanoma for unresectable or metastatic melanoma. These products are in clinical development stages, focusing on evaluating safety, expansion, persistence, and clinical activity in targeted patient populations. The company operates as a clinical stage biotechnology firm with a focus on allogeneic chimeric antigen receptor T-cell therapies and gene therapy product candidates. Cellectis SA's primary revenue stream comes from the development and potential future commercialization of its gene-editing therapies. The company is currently in the clinical stage, meaning it does not yet have commercialized products generating revenue. Instead, it relies on funding from research grants, partnerships, and equity financing to support its ongoing clinical trials and development activities. The company's focus on specific cancer types such as ALL, B-NHL, LBCL, RCC, and melanoma targets patients with unmet medical needs, positioning itself for potential future partnerships with pharmaceutical companies for further development and commercialization. The company's target segments include patients with relapsed or refractory cancers, specifically those suffering from r/r ALL, B-NHL, LBCL, RCC, and melanoma. These segments represent significant unmet medical needs in oncology, with Cellectis SA aiming to provide novel therapeutic options through its gene-editing platform. The company's development pipeline is designed to address these specific indications, with each product candidate targeting a distinct patient population requiring innovative treatments. Cellectis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cellectis stock

Total Operating Expenses of Cellectis is 102.11 M USD in 2025.

Total Operating Expenses of Cellectis changed from 98.96 M USD to 102.11 M USD, representing a 3.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses Cellectis since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's Cellectis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Cellectis

All Key Metrics — Cellectis